Soligenix announces positive top-line results for its pivotal phase 3 flash trial evaluating sgx301 in treatment of cutaneous t-cell lymphoma

Soligenix announces positive top-line results for its pivotal phase 3 flash trial evaluating sgx301 in treatment of cutaneous t-cell lymphoma.soligenix inc - statistically significant treatment response achieved in primary endpoint of sgx301.soligenix inc - sgx301 was well-tolerated and its mechanism of action is not associated with dna damage like other currently available therapies.
SNGX Ratings Summary
SNGX Quant Ranking